OmniAb, Inc. (OABI)
(Delayed Data from NSDQ)
$4.06 USD
-0.13 (-3.10%)
Updated Jun 20, 2024 04:00 PM ET
After-Market: $4.06 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
OABI 4.06 -0.13(-3.10%)
Will OABI be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for OABI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OABI
USANA Health Sciences (USNA) Q1 Earnings and Revenues Top Estimates
Plus Therapeutics (PSTV) Reports Q4 Loss, Tops Revenue Estimates
OABI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates
OmniAb, Inc. (OABI) Soars 10.5%: Is Further Upside Left in the Stock?
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates
Other News for OABI
OmniAb Announces Publication of Scientific Paper on Heavy Chain-Only Single-Domain Antibody Chicken Platform in the Journal of Immunology
CDXS, SMMT and OABI are among after hour movers
Fly Intel: After-Hours Movers
OmniAb CEO buys $1.06M in common stock
OmniAb to Participate in the Jefferies Global Healthcare Conference